Renin inhibition with aliskiren: Where are we now, and where are we going?

Journal of Hypertension

Volumn 24, Issue 2, 2006, Pages 243-256

  Azizi, Michel ^a   Webb, Randy ^b   Nussberger, Juerg ^c   Hollenberg, Norman K ^d,e  

^a HÔPITAL EUROPÉEN GEORGES POMPIDOU   (France)

^b NOVARTIS INSTITUTES FOR BIOMEDICAL RESEARCH   (United States)

^c LAUSANNE UNIVERSITY HOSPITAL   (Switzerland)

^d HARVARD MEDICAL SCHOOL   (United States)

^e BRIGHAM AND WOMEN S HOSPITAL   (United States)

Author keywords

Angiotensin; Hypertension; Renin inhibition; Renin angiotensin aldosterone system

Indexed keywords

ALISKIREN; ANGIOTENSIN 1 RECEPTOR ANTAGONIST; ANGIOTENSIN RECEPTOR ANTAGONIST; BENAZEPRIL; CANDESARTAN; CGP 38560; CIPROKIREN; DIPEPTIDYL CARBOXYPEPTIDASE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; ENALAPRIL; ENALAPRILAT; ENALKIREN; IRBESARTAN; LOSARTAN; REMIKIREN; RENIN; RENIN INHIBITOR; TERLAKIREN; VALSARTAN; ZANKIREN;

ANEMIA; ANGIONEUROTIC EDEMA; BLOOD PRESSURE; CLINICAL TRIAL; COMPARATIVE STUDY; COUGHING; DRUG EFFECT; DRUG EFFICACY; DRUG SCREENING; ENZYME INHIBITION; ENZYME RELEASE; ENZYME SYNTHESIS; ESSENTIAL HYPERTENSION; HUMAN; HYPERKALEMIA; HYPERTENSION; METHODOLOGY; NONHUMAN; PRIORITY JOURNAL; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; REVIEW; SODIUM DEPLETION;

EID: 33644789557     PISSN: 02636352     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.hjh.0000202812.72341.99     Document Type: Review

References (75)

1. Skeggs LT, Kahn JR, Lerrtz KE, Shumway NP. Preparation, purification, and amino acid sequence of a polypeptide renin substrate. J Exp Med 1957; 106:439-453.
2. Flather MD, Yusuf S, Kober L, Pfeffer M, Hall A, Murray G, et al. Long-term ACE-inhibitor therapy in patients with heart failure or left ventricular dysfunction: a systematic overview of data from individual patients. ACE inhibitor Myocardial Infarction Collaborative Group. Lancet 2000; 355:1575-1581.
3. ACE Inhibitor Myocardial Infarction Collaborative Group. Indications for ACE inhibitors in the early treatment of acute myocardial infarction: Systematic overview of individual data from 100,000 patients in randomized trials. Circulation 1998; 97:2202-2212.
4. Lee VC, Rhew DC, Dylan M, Badamgarav E, Braunstein GD, Weingarten SR. Meta analysis: angiotensin receptor blockers in chronic heart failure and high risk acute myocardial infarction. Ann Intern Med 2004; 141:693-704.
5. Lewis EJ, Hunsicker LG, Bain RP, Rohde RD. The effect of angiotensin converting enzyme inhibition on diabetic nephropathy. The Collaborative Study Group. N Engl J Med 1993; 329:1456-1462.
6. Lewis EJ, Hunsicker LG, Clarke WR, Berl T, Pohl MA, Lewis JB, et al. Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes. N Engl J Med 2001; 345:851-860.
7. Brenner BM, Cooper ME, deZeeuw D, Keane WF, Mitch WE, Parving HH, et al. Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N Engl J Med 2001; 345:861-869.
8. The GISEN Group. Randomized placebo-controlled trial of effect of ramipril on decline in glomerular filtration rate and risk of terminal renal failure in proteinuric, nondiabetic nephropathy. Lancet 1997; 349:1857-1863.
9. Yusuf S, Sleight P, Pogue J, Bosch J, Davies R, Dagenais G. Effects of an angiotensin converting enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. The Heart Outcomes Prevention Evaluation Study Investigators. N Engl J Med 2000; 342:145-153.
10. Fisher NDL, Hollenberg NK. Is there a future for renin inhibitors? Exp Opin Invest Drugs 2001; 10:417-426.
11. Maibaum J, Feldman DL. Renin inhibitors as novel treatments for cardiovascular disease. Exp Opin Ther Patients 2003; 13:589-603.
12. Kleinert HD, Stein HH, Specific renin inhibitors: Concepts and prospects. In: Laragh JH, Brenner BM, editors. Hypertension, pathophysiology, diagnosis and management, Vol. 2. New York: Raven Press; 1995. pp. 3065-3077.
13. Lin C, Frishman WH. Renin inhibition: a novel therapy for cardiovascular disease. Am Heart J 1996; 131:1024-1034.
14. Haber E. Peptide inhibitors of renin in cardiovascular studies. Fed Proc 1983; 42:3155-3161.
15. Ngo TT, Tunnicliff G. Inhibition of enzymatic reactions by transition state analogs: an approach for drug design. Gen Pharmacol 1931; 12:129-138.
16. Wood JM, Gulatin N, Forgiarini P, Fuhrer W, Hofbauer KG. Effects of a specific and long-acting renin inhibitor in the marmoset. Hypertension 1985; 7:797-803.
17. Delabays A, Nussberger J, Porchet M, Waeber B, Hoyos P, Boger R, et al. Hemodynamic and humoral effects of the new renin inhibitor enalkiren in normal humans. Hypertension 1989; 13:941-947.
18. Wood JM, Criscione L, de Gasparo M, Bühlmayer P, Rüeger H, Stanton JL, et al. CGP 38560: orally active, low-molecular-weight renin inhibitor with high potency and specificity. J Cardiovasc Pharmacol 1989; 14: 221-226.
19. Kobrin I, Viskoper RJ, Laszt A, Bock J, Weber C, Charlon V. Effects of an orally active renin inhibitor, Ro 42-5892, in patients with essential hypertension. Am J Hypertens 1993; 6:349-356.
20. Menard J, Boger RS, Moyse DM, Guyene TT, Glassman HN, Kleinert HD. Dose-dependent effects of the renin inhibitor zankiren HCl after a single oral dose in mildly sodium-depleted normotensive subjects. Circulation 1995; 91:330-338.
21. Fischli W, Clozel JP, Breu V, Buchmann S, Mathews S, Stadler H, et al. Cirprokiren (Ro 44-9375): A renin inhibitor with increasing effects on chronic treatment. Hypertension 1994; 24:163-169.
22. Murphy WR, Wester RT, Rosati RL, Hoover DJ, Purcell IM, MacAndrew JT, et al. Hemodynamic effects of the renin inhibitor CP-80,794 in several species. In: Lubek G, Rosenthal GA, editors. Aminoacids: chemistry, biology and medicine. ESCOM; 1990, pp. 676-688.
23. Rahuel J, Rasetti V, Maibaum J, Rueger H, Goschke R, Cohen NC, et al. Structure-based drug design: the discovery of novel nonpeptide orally active inhibitors of human renin. Chem Biol 2000; 7:493-504.
24. Wood JM, Maibaum J, Rahuel J, Grutter MG, Cohen NC, Rasetti V, et al. Structure-based design of aliskiren, a novel orally effective renin inhibitor. Biochem Biophys Res Comm 2003; 308:698-705.
25. Wood JM, Schnell CR, Cumin F, Menard J, Webb RL. Aliskiren, a novel orally effective renin inhibitor, lowers blood pressure in marmosets and spontaneously hypertensive rats. J Hypertens 2005; 23:417-426.
26. Ganten D, Wagner J, Zeh K, Bader M, Michel JB, Paul M, et al. Species specificity of renin kinetics in transgenic rats harboring the human renin and angiotensinogen genes. Proc Natl Acad Sci USA 1992; 89:7806-7810.
27. Rigel DF, Fu F, Li S, Maniara W, Muller DN, Luft FC. The renin inhibitor aliskiren is a potent and long-acting antihypertensive in double transgenic rats expressing human renin and angiotensinogen genes. J Am Coll Cardiol 2004; 43:483A.
28. Pilz B, Shagdasurren E, Wellner M, Fiebeler A, Meiners S, Feldman DL, et al. Aliskiren, a human renin inhibitor, reverses angiotensin II-induced renal and cardiac damage in dTGR in a regression study design [abstract]. Hypertension 2004; 44:526-527.
29. Webb RL, Navarrete AE, Davis S, de Gasparo M. Synergistic effects of combined converting enzyme inhibition and angiotensin II antagonism on blood pressure in conscious telemetered spontaneously hypertensive rats. J Hypertens 1998; 16:843-852.
30. Azizi M, Chatellier G, Guyene TT, Menard J. Additive effects of combined angiotensin converting enzyme inhibition and angiotensin II antagonism on blood pressure and renin release in sodium-depleted normotensives. Circulation 1995; 92:825-834.
31. Juillerat L, Nussberger J, Menard J, Mooser V, Christen Y, Weber B, et al. Determinants of angiotensin II generation during converting enzyme inhibition. Hypertension 1990; 16:564-572.
32. Fossa AA, DePasquale MJ, Ringer LI, Winslow RL. Synergistic effect on reduction in blood pressure with coadministration of a renin inhibitor or an angiotensin-converting enzyme inhibitor with an angiotensin II receptor antagonist. Drug Dev Res 1994; 33:422-428.
33. Nguyen G, Delarue F, Berrou J, Rondeau E, Sraer JD. Specific receptor binding of renin on human mesangial cells in culture increases plasminogen activator inhibitor-1 antigen. Kidney Int 1996; 50:1897-1903.
34. Nguyen G, Delarue F, Burcklé C, Bouzhir L, Giller T, Sraer JD. Pivotal role of the renin/prorenin receptor in angiotensin II production and cellular responses to renin. J Clin Invest 2002; 109:1417-1427.
35. Fisher NDL, Hollenberg NK. Renin inhibition: What are the therapeutic opportunities? J Am Soc Nephrol 2005; 16:592-599.
36. Okunishi H, Miyazaki M, Toda N. Evidence for a putatively new angiotensin II-generating enzyme in the vascular wall. J Hypertens 1984; 2:277-284.
37. Urata H, Kinoshita A, Misono KS, Bumpus FM, Husain A. Identification of a highly specific chymase as the major angiotensin II-forming enzyme in the human heart. J Biol Chem 1990; 265:22348-22357.
38. Hollenberg NK, Fisher NDL, Price DA. Pathways for angiotensin II generation in intact human tissue: evidence from comparative pharmacological interruption of the renin system. Hypertension 1998; 32:387-392.
39. Saris JJ, van Dijk MA, Kroon I, Schalekamp MA, Danser AH. Functional importance of angiotensin-converting enzyme-dependent in situ angiotensin II generation in the human forearm. Hypertension 2000; 35:764-768.
40. Soffer RL. Angiotensin-converting-enzyme and the regulation of vasoactive peptides. Annu Rev Biochem 1976; 45:73-94.
41. Linz W, Wiemer G, Gohlke P, Unger T, Scholkens BA. Contribution of kinins to the cardiovascular actions of angiotensin-converting enzyme inhibitors. Pharmacol Rev 1995; 47:25-49.
42. (1-7) unmasked during combined treatment with lisinopril and losartan. Hypertension 1998; 31:699-705.
43. Siragy HM, de Gasparo M, Carey RM. Angiotensin type 2 receptor mediates valsartan-induced hypotension in conscious rats. Hypertension 2000; 35:1074-1077.
44. Maruta H, Arakawa K. Confirmation of direct angiotensin formation by kallikrein. Biochem J 1983; 213:193-200.
45. Vinci JM, Horowitz D, Zusman RM. The effects of converting enzyme inhibition with SQ 20881 on plasma and urinary kinins, prostaglandin E, and angiotensin II in hypertensive man. Hypertension 1979; 1:416-426.
46. Boger RS, Glassman HN, Cavanaugh JH, Schmitz PJ, Lamm J, Moyse D, et al. Prolonged duration of blood pressure response to enalkiren, the novel dipeptide renin inhibitor, in essential hypertension. Hypertension 1990; 15:835-840.
47. Nussberger J, Brunner DB, Waeber B, Brunner HR. Specific measurement of angiotensin metabolites and in vitro generated angiotensin II in plasma. Hypertension 1986; 8:476-482.
48. Nussberger J, Brunner DB, Waeber B, Brunner HR. In vitro renin inhibition to prevent generation of angiotensins during determination of angiotensin I and II. Life Sci 1988; 42:1683-1688.
49. Hui KY, Delvin R, Nussberger J, Hartley H, Vatner SF, Haber E. Effects of renin inhibition in the conscious primate Macaca fascicularis. Hypertension 1989; 14:480-487.
50. Fitzpatrick MA, Rademaker MT, Charles CJ, Yandle TG, Espiner EA, Ikram H, Nussberger J. Comparison of the effect of renin inhibition and angiotensin-converting enzyme inhibition in ovine heart failure. J Cardiovasc Pharmacol 1992; 19:169-175.
51. Zusman RM, Hui KY, Nussberger J, Christensen D, Higgins J, Carlson WD, et al. R-PEP-27, a potent renin inhibitor, decreases plasma angiotensin II and blood pressure n normal volunteers. Am J Hypertens 1994; 7:295-301.
52. Christen Y, Waeber B, Nussberger J, Maggon K, Shum L, Timmermans PB, Brunner HR. Oral administration of DuP753, a specific angiotensin II receptor antagonist, to normal male volunteers. Inhibition of pressure response to exogenous angiotensin I and II. Circulation 1991; 83:1333-1342.
53. Azizi M, Bissery A, Bura-Rivière A, Ménard J. Dual renin-angiotensin system blockade restores blood pressure-renin dependency in individuals with low renin concentrations. J Hypertens 2003; 21:1887-1895.
54. Jeunemaître X, Ménard J, Nussberger J, Guyene TT, Brunner HR, Corvol P. Plasma angiotensins, renin and blood pressure during acute renin inhibition by CGP 38560A in hypertensive patients. Am J Hypertens 1989; 2:819-827.
55. Poulsen K, Joergensen J. An easy radioimmunological microassay of renin activity, concentration and substrate in human and animal plasma and tissues based on angiotensin I trapping by antibody. J Clin Endocrinol Metab 1974; 39:816-825.
56. Nussberger J, Delabays A, de Gasparo M, Cumin F, Waeber B, Brunner HR, Ménard J. Hemodynamic and biochemical consequences of renin inhibition by infusion of CGP 38560A in normal volunteers. Hypertension 1989; 13:948-953.
57. Ménard J, Guyenne TT, Corvol P, Pau B, Simon D, Roncucci R. Direct immunometric assay of active renin in human plasma. J Hypertens 1985; 3 (suppl 3):275-278.
58. Nussberger J, Wuerzner G, Jensen C, Brunner HR. Angiotensin II suppression in humans by the orally active renin inhibitor aliskiren (SPP100): comparison with enalapril. Hypertension 2003; 39:E1-E8.
59. Vaidyanathan S, Jin Y, Schiller H, Jensen C. Aliskiren, a novel oral renin inhibitor, has no interaction with cytochrome P450 isoenzymes in vitro. Bas Clin Pharmacol Toxicol (in press).
60. Forclaz A, Maillard M, Nussberger J, Brunner HR, Burnier M. Angiotensin II receptor blockade: Is there truly a benefit of adding an ACE inhibitor. Hypertension 2003; 41:31-36.
61. Maillard MP, Mazzolai L, Daven V, Centeno C, Nussberger J, Brunner HR, Burnier M. Assessment of angiotensin II receptor blockade in humans using a standardized angiotensin II receptor-binding assay. Am J Hypertens 1999; 12:1201-1208.
62. Bing J. Rapid marked increase in plasma renin in rats treated with inhibitors of the renin system. Effects of 1-sar-8-ala-angiotensin II and of a synthetic converting enzyme inhibitor (nonapeptide, SQ 20. 881) on normal and adrenalectomized rats. Acta Pathol Microbiol Scand [A] 1973; 81:376-378.
63. Laragh JH, Lamport B, Sealey J, Alderman MH. Diagnosis ex juvantibus. Individual response patterns to drugs reveal hypertension mechanisms and simplify treatment. Hypertension 1988; 12:223-226.
64. Meredith PA, Reid JL. The use of pharmacodynamic and pharacokinetic profiles in drug development for planning individual therapy. In: Laragh JH, Brenner BM, editors. Hypertension: pathophysiology, diagnosis, and management. New York: Raven Press; 1995, pp. 2771-2783.
65. Azizi M, Menard J, Bissery A, Bura-Riviere A, Vaidyanathan S, Camisasca RP. Pharmacologic demonstration of the synergistic effects of a combination of the renin inhibitor aliskiren and the AT1 receptor antagonist valsartan on the angiotensin II-renin feedback interruption. J Am Soc Nephrol 2004; 15:3126-3133.
66. Fisher ND, Allan DR, Gaboury CL, Hollenberg NK. Intrarenal angiotensin II formation in humans. Evidence from renin inhibition. Hypertension 1995; 25:935-939.
67. Aviv A, Hollenberg NK, Weder AB. Sodium glomerulopathy: tubuloglomerular feedback and renal injury in African Americans. Kidney Int 2004; 65:361-368.
68. van Paasen P, de Zeeuw D, Navis G, de Jong PE. Renal and systemic effects of continued treatment with renin inhibitor remikiren in hypertensive patients with normal and impaired renal function. Nephrol Dial Transplant 2000; 15:637-647.
69. Stanton A, Jensen C, Nussberger J, O'Brien E. Blood pressure lowering in essential hypertension with an oral renin inhibitor, aliskiren. Hypertension 2003; 42:1137-1143.
70. Gradman AH, Schmieder RE, Lins RL, Chiang Y, Bedigian MP. Aliskiren, a novel, orally-effective renin inhibitor, provides antihypertensive efficacy and placebo-like tolerability similar to an AT1-receptor blocker in hypertensive patients. Circulation 2005; 111:1012-1018.
71. Azizi M, Menard J. Combined blockade of the renin-angiotensin system with angiotensin-converting enzyme inhibitors and angiotensin II type 1 receptor antagonists. Circulation 2004; 109:2492-2499.
72. McMurray JJ, Ostergren J, Swedberg K, Granger CB, Held P, Michelson EL, et al. Effects of candesartan in patients with chronic heart failure and reduced left ventricular systolic function taking angiotensin converting enzyme inhibitors: the CHA-Added Trial. Lancet 2003; 362:767-771.
73. Nakao N, Yoshimura A, Moita H, Takada M, Kayano T, Ideura T. Combination treatment of angiotensin II receptor blocker and angiotensin converting enzyme inhibitor in non-diabetic renal disease (COOPERATE): a randomized controlled trial. Lancet 2003; 361:117-124.
74. Moran T, Griffiths C, Delbridge L. Low doses of angiotensin converting enzyme inhibitors and angiotensin type 1 blockers have a synergistic effect but high doses are less than additive. Am J Hypertens 2002; 15:1003-1005.
75. Hollenberg NK. Aldosterone in the development and progression of renal injury. Kidney Int 2004; 66:1.